Respiratory Drug Delivery 2010 - In Review
Respiratory Drug Delivery 2010 was held at the Omni Orlando Resort at ChampionsGate, Orlando, Florida, during April 25-29, 2010. In spite of volcano ash and a global recession, approximately 700 registrants from all over the world gathered in Florida to review the latest topics in nasal and pulmonary drug delivery. Approximately 58% of the attendees were from the USA and Canada, while 38% were from Europe and 4% Australasia, India, China and South America. Pharmaceutical industry participants made up the bulk of the audience (45% Research & Development, 22% Sales, Marketing and Business professionals, 11% Management, and 6% Engineers, Process / Packaging, QbD) but we saw increased regulatory (6%) and academic (10%) participation in what continues to emerge as a thriving field of scientific and clinical endeavor.
The organizers of the meeting and Virginia Commonwealth University were honored to award the 2010 “Charles G. Thiel Award", endowed at VCU by 3M Drug Delivery Systems, for outstanding research and discovery in respiratory drug delivery to Michael T. Newhouse who pioneered the development of AeroChamber - the device that is now a mainstay of asthma therapy and enables patients to use their metered dose inhalers successfully.
Professor Norbert Voelkel, from Virginia Commonwealth University, presented the plenary lecture on the topic 'Pulmonary Hypertension, Etiology and Pathogenesis: New Treatments and Targets'. Top-quality speakers provided perspectives on the modulation of systemic drug delivery via the lung, the treatment of infections and cancer, and identified important lung transporters. Economic and environmental issues associated with inhaler development in Article 5 countries including China and India were addressed and a lively panel discussion chaired by Professor Ashley Woodcock followed - this session was audio recorded and will be available online later this summer.
Other experts shared their insights on patient focused nasal delivery, new solutions to manufacturing and testing problems, drug deposition modeling and fundamental pharmaceutics of MDIs and DPIs.
In conjunction with the Product Quality Research Institute (PQRI), RDD 2010 took an in-depth look at the potential for pharmacokinetics to serve as the sole in vivo metric necessary to support a finding of bioequivalence (BE) between inhaled products. Expert opinions on this controversial issue were discussed and the speakers were joined in debate by FDA experts for a short panel discussion at the end of the formal presentations. As a result of PQRI sponsorship, the session was audio recorded and is available online as a series of audio lectures and synchronized powerpoint slides. Discussions on this topic continued on Friday April 30 in a PQRI coordinated Workshop and included case studies and a series of breakout sessions with focused discussions on PK and lung deposition, PK and in vitro assessment, PK and PD relationships and effective PK study design.
Posters on the Podium was back again this year alongside RDD’s signature Technology Exhibition and Scientific Poster Session. We hosted more than 85 company displays in the Technology Exhibition and were pleased to welcome many posters and exhibitors from institutions that had not previously attended US RDD conferences.
Peer reviewed papers from all the speaker presentations, as well as extended poster abstracts are available electronically and hard copies of the proceedings can be purchased on RDD Online.
The organizers thank all our presenters, exhibitors, and sponsors for their contribution to RDD 2010, and we look forward to meeting you all again at Respiratory Drug Delivery Europe 2011 at the Intercontinental Hotel, in Berlin Germany May 3-6, 2011.